Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  everolimus
Find trials that include:  Any drugs shown
Results 1-25 of 65 for your search:
Start Over
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Phase: Phase IV
Type: Treatment
Age: Not specifiec
Trial IDs: CRAD001C2X01B, NCI-2013-01151, NCT01789281
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140
Everolimus and Gemcitabine Hydrochloride in Treating Patients With Refractory Primary or Secondary In Situ Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-165, NCI-2010-02341, NCT01259063
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BTTC09-01, NCI-2011-03056, NCT01434602
Combination Chemotherapy Followed by Radiation Therapy, Carboplatin, and Everolimus in Treating Patients with Esophageal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CRAD001CUS159T, NCI-2012-00166, WCI1871-10, NCT01490749
Everolimus and Hydroxychloroquine in Treating Patients With Previously Treated Kidney Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 07811, NCI-2012-00170, NCT01510119
Panobinostat and Everolimus in Treating Patients with Metastatic or Unresectable Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 146308, NCI-2009-01599, NCT01037257, NCT01582009
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients with Pancreatic Neuroendocrine Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 andover
Trial IDs: 201303150, NCI-2013-00641, NCT01784861
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: COEB071X2103, NCI-2013-02490, NCT01854606
Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RX-0201-P2-A-09, NCI-2014-02443, NCT02089334
Everolimus Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-23409, NCI-2012-00764, 06-08-20-01, NCT00831480
Everolimus with or without Trastuzumab in Treating Patients with Hormone-Refractory Metastatic Breast Cancer Receiving Hormone Therapy
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: WCI1524-08/H4459S, NCI-2011-03381, WCI 1524-08, NCT00912340
Everolimus and Panobinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: Pro00012947, NCI-2013-02164, NCT00978432
Everolimus in Treating Younger Patients With Neurofibromatosis Type 1 or Low Grade Gliomas That Did Not Responded to Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: 09452, NCI-2010-01929, DOD W81XWH-05-1-0615, NCT01158651
Everolimus With or Without Paclitaxel as First-Line Therapy in Treating Patients Advanced Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU10-147, NCI-2013-00308, 1008-13, 1011004329, NCT01215136
Everolimus and Pasireotide in Treating Patients with Metastatic Intraocular Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-123, NCI-2010-02317, NCT01252251
Pasireotide and Everolimus in Treating Patients with Thyroid Cancer Refractory to Radioiodine
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WCI1777-09, NCI-2011-03377, IRB00041909, NCT01270321
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
GSK1120212 Rollover Study
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Everolimus and Bevacizumab in Treating Patients with Advanced Kidney Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-226, NCI-2011-01944, NCT01399918
Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: SARC016, NCI-2014-00697, NCT01661283
Rituximab and Everolimus in Treating Patients with B-Cell Lymphoma, Gray Zone Lymphoma, or Hodgkin Lymphoma Receiving High-Dose Therapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1228, NCI-2012-02757, CIR00004190, CRAD001NUS157T, NA_00067315, NCT01665768
Everolimus in Treating Younger Patients With Recurrent or Progressive Low-Grade Gliomas
Phase: Phase II
Type: Tissue collection/Repository, Treatment
Age: 3 to 21
Trial IDs: 120817, NCI-2012-02774, PNOC001, NCT01734512
Start Over